Entrectinib

(Rozlytrek)

Entrectinib

Drug updated on 11/14/2023

Dosage FormCapsule (oral: 100 mg, 200 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
  • For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation.
  • For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that are metastatic or where surgical resection is likely to result in severe morbidity.
  • For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have progressed following treatment or have no satisfactory alternative therapy.